lipoxygenase inhibitor lox inhibitor pipeline insight

DelveInsight’s, “Lipoxygenase Inhibitor (LOX Inhibitor) - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Lipoxygenase Inhibitor (LOX Inhibitor) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Lipoxygenase Inhibitor (LOX Inhibitor) Understanding

Lipoxygenase Inhibitor (LOX Inhibitor): Overview

Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. Lipoxygenase (LOX) can catalyze fatty acid to produce a number of active metabolic products that are involved in a lot of vital diseases. For instance, type 1 and type 2 diabetes (or both), cardiovascular diseases, hypertension, renal diseases, and neurological conditions such as Alzheimer's disease and Parkinson's disease. In particular, LOX is a kind of rate-limiting enzyme in the process of arachidonic acid (AA) metabolism into leukotriene (LT) which mediates the occurrence of inflammation. All subtypes of LOXs have a single polypeptide chain, which is folded into two major domains: C-terminal catalytic domain and N-terminal β-barrel domain. Human LOXs are metalloenzymes of 60–100 kDa, ranging from 662 to 675 amino acid residues and sharing 35–80% sequential identity. LOXs are a type of non-heme iron enzyme which dominate the metabolism of unsaturated fatty acids by different regiospecificities and stereospecificities. The three main functions of LOXs are oxidization of substrates, transformation of hydroperoxy lipids and synthesis of LTs.

 

“Lipoxygenase inhibitor - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Lipoxygenase inhibitor pipeline landscape is provided which includes the disease overview and Lipoxygenase inhibitor treatment guidelines. The assessment part of the report embraces, in depth Lipoxygenase inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lipoxygenase inhibitor  collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lipoxygenase inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Lipoxygenase inhibitor. 

Lipoxygenase inhibitor Emerging Drugs Chapters

This segment of the Lipoxygenase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Lipoxygenase inhibitor Emerging Drugs

 

Vatiquinone: PTC Therapeutics

Vatiquinone is an investigational small molecule that inhibits 15-Lipoxygenase, an enzyme that is a key regulator of the oxidative stress and inflammation response pathways that underpin neurological disease pathology. Vatiquinone has been evaluated in a number of clinical studies in which it has been demonstrated to have an impact on mortality risk and a number of neurological and neuromuscular disease symptoms. In more than 500 patients with duration of exposure up to 10 years, vatiquinone has demonstrated a favorable safety profile. Vatiquinone is currently being developed in Phase III stage of development for the treatment of Friedreich Ataxia, Inherited Mitochondrial Disease.

 

Epeleuton: Afimmune

Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a novel synthetic fatty acid drug product targeting 5-lipoxygenase. Afimmune is prioritising Epeleuton for SCD due to its superior preclinical efficacy, first-in-class opportunity and a significantly reduced regulatory pathway. Epeleuton has received orphan drug designation for the treatment of SCD from the FDA and EMA. Epeleuton has been shown to have a unique mechanism of action for the treatment of SCD, targeting factors affecting severity, course of disease and vaso-occlusive crisis risk. In the humanized SCD mice, Epeleuton protected against inflammatory response, vascular activation, abnormal red cell morphology, hemolysis and sickling.

Further product details are provided in the report……..

Lipoxygenase inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Lipoxygenase inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Lipoxygenase inhibitor 

There are approx. 5+ key companies which are developing the therapies for Lipoxygenase inhibitor. The companies which have their Lipoxygenase inhibitor drug candidates in the most advanced stage, i.e. Phase III include, PTC Therapeutics.

 

Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration
Lipoxygenase inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lipoxygenase Inhibitor (LOX Inhibitor): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipoxygenase Inhibitor (LOX Inhibitor) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipoxygenase Inhibitor (LOX Inhibitor) drugs.

Lipoxygenase Inhibitor (LOX Inhibitor) Report Insights

• Lipoxygenase Inhibitor (LOX Inhibitor) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lipoxygenase Inhibitor (LOX Inhibitor) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Lipoxygenase Inhibitor (LOX Inhibitor) drugs?
• How many Lipoxygenase Inhibitor (LOX Inhibitor) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Lipoxygenase Inhibitor (LOX Inhibitor)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipoxygenase Inhibitor (LOX Inhibitor) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lipoxygenase Inhibitor (LOX Inhibitor) and their status?
• What are the key designations that have been granted to the emerging drugs?